Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
Ibritumomab tiuxetan (Zevalin®) has not been endorsed for use within NHS Wales as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of ibritumomab tiuxetan (Zevalin®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services. |
||
|
||
Medicine details |
||
| Medicine name | ibritumomab tiuxetan (Zevalin®) | |
| Formulation | 1.6 mg/ml radiopharmaceutical preparations for infusion | |
| Reference number | 159 | |
| Indication | Consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 18/05/2009 | |